Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
Saphenous vein graft disease remains an unresolved medical problem. Many vein grafts occlude
in the first year after bypass surgery, leading to adverse cardiovascular outcomes, including
recurrent angina, myocardial infarction, and the need for repeat coronary intervention. While
aspirin is the standard antiplatelet treatment after CABG surgery, 10-20% of vein grafts
continue to occlude despite contemporary secondary preventative therapy. Compared to aspirin
and other antiplatelet therapies like clopidogrel, ticagrelor treatment leads to a more
pronounced platelet inhibition, and may substantially improve graft patency following CABG
compared to aspirin. No data has yet to be collected regarding the impact of ticagrelor on
saphenous vein graft patency following CABG. In this context, the investigators seek to
compare vein graft patency between patients randomized to receive aspirin therapy, the
current standard of care, or ticagrelor treatment, starting in the early postoperative
period, and continuing for 2 years after CABG.
Phase:
Phase 4
Details
Lead Sponsor:
Boca Raton Regional Hospital
Collaborators:
AstraZeneca Ottawa Heart Institute Research Corporation